US FDA's device center is moving quickly on a major reorganization that will essentially dissolve and replace the Office of Compliance, Office of Surveillance and Biometrics, and Office of Device Evaluation into one "super office" that would fulfill a "Total Product Life Cycle" (TPLC) scheme the agency has long envisioned.
The yet-unnamed office would have jurisdiction not just to review and greenlight products in the pre-market stage, but continue to assess them and the manufacturers that make them after they've...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?